- Your selection
- Clear all
- Pharmaceuticals x
- Global x
- With Teaching Note x
- Economics & Finance x
2 case(s) found.
This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.
-
Reference 6033
-
Published 27 Jan 2014
-
Length 4 page(s)
-
Topic Economics & Finance
-
Region Global
-
Industry Pharmaceuticals
This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.
This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.
-
Reference 6033
-
Published 27 Jan 2014
-
Length 5 page(s)
-
Topic Economics & Finance
-
Region Global
-
Industry Pharmaceuticals
This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.